Mapoli

Sitagliptin, the active ingredient in Mapoli, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control.

GNH USA supplies Mapoli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mapoli (sitagliptin) is used within the antidiabetic therapeutic pathway to manage hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Combination therapy with metformin: provides additive glycaemic control when monotherapy is insufficient. - Adjunct to diet and exercise: supports overall diabetes management alongside lifestyle measures.

Adverse reactions may occur with sitagliptin therapy.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient cranial discomfort. - Gastrointestinal upset: nausea, diarrhoea or abdominal pain. - Dizziness: occasional light‑headed sensation. - Upper respiratory infection: cough or sore throat.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angio‑edema or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent. - Bullous pemphigoid: rare blistering skin disorder. - Hepatic injury: abnormal liver function tests or hepatitis.

Before initiating sitagliptin, consider the following safety measures. - Renal impairment: dose adjustment may be required based on creatinine clearance. - Hepatic impairment: monitor liver enzymes in patients with existing liver disease. - Cardiovascular disease: use cautiously in patients with a history of heart failure. - Elderly patients: start at the lowest effective dose and monitor for adverse events. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sitagliptin exposure. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): raise plasma concentrations. - Sulfonylureas or insulin secretagogues: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may affect glucose homeostasis. - ACE inhibitors or ARBs: monitor renal function and potassium. - NSAIDs: potential additive renal stress, especially in compromised patients.